Researchers published a Nature Biotechnology paper reporting a self-assembling peptide micelle that codelivers an antifungal drug and a host‑defense peptide mimic to achieve combinatorial antifungal therapy. The study demonstrates enhanced fungal killing in preclinical models with reduced drug toxicity versus single‑agent approaches. The authors show that the micelle both stabilizes payloads and concentrates activity at infection sites, improving therapeutic index. The paper includes in vitro potency, pharmacology and in vivo efficacy data and positions micelle‑based codelivery as a platform to revive or improve existing antifungals. For drug developers, the work suggests a path to combine host‑directed and small‑molecule antifungal strategies while mitigating systemic toxicity risks. The platform could accelerate IND‑enabling work for hard‑to‑treat invasive fungal infections.